Status:

COMPLETED

Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early

Lead Sponsor:

Hellenic Institute for the Study of Sepsis

Conditions:

COVID-19

Virus Diseases

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Recent information appearing from different countries suggest that treatment of Coronavirus disease 2019 (COVID-19) with hydroxychloroquine or with a combination of hydroxychloroquine and azithromycin...

Detailed Description

Humanity is experiencing since December 2019 a new pandemic by the novel SARS Coronavirus-19 (SARS-CoV-2). As of March 25 2020 418,099 documented case were reported worldwide; 18,608 patients died. Th...

Eligibility Criteria

Inclusion

  • Age ≥18 years
  • Male of female gender
  • Written informed consent provided by the patients or by a first-degree relative in case of patients unable to consent
  • In case of women, unwillingness to remain pregnant during the study period achieved either by their partner using condom or by themselves using oral contraceptives.
  • Confirmed infection by SARS-CoV-2 virus
  • Infection of the upper respiratory tract or of the lower respiratory tract

Exclusion

  • Age below 18 years
  • Denial of written informed consent
  • Intake of any macrolide for the current episode of infection under study
  • Intake of hydroxychloroquine or chloroquine phosphate.
  • Presence of severe respiratory failure
  • Oral or intravenous intake of corticosteroids defined as any more than 0.4mg/kg daily intake of equivalent prednisone for the last 15 days
  • Neutropenia defined as an absolute neutrophil count below 1,000/mm3
  • Presence of any contraindications for the study drugs as stated in local label information
  • QTc interval at rest electrocardiogram ≥500 msec or history of known congenital long QT syndrome
  • Pregnancy or lactation

Key Trial Info

Start Date :

May 6 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 30 2020

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT04398004

Start Date

May 6 2020

End Date

November 30 2020

Last Update

January 11 2021

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING

Marousi, Athens, Greece, 15126

2

2nd Department of Internal Medicine, General Hospital of Nikaia

Piraeus, Attica, Greece, 18454

3

2nd Department of Internal Medicine, University General Hospital of Alexandroupolis

Alexandroupoli, Greece, 68100

4

1st University Department of Internal Medicine, LAIKO General Hospital of Athens

Athens, Greece, 11527